Market capitalization | $9.16m |
Enterprise Value | $7.39m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 4.77 |
P/S ratio (TTM) P/S ratio | 5.91 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | -13.17% |
Revenue (TTM) Revenue | $1.55m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
3 Analysts have issued a Addex Therapeutics Ltd - ADR forecast:
3 Analysts have issued a Addex Therapeutics Ltd - ADR forecast:
Mar '24 |
+/-
%
|
||
Revenue | 1.55 1.55 |
13%
13%
|
|
Gross Profit | - - |
-
|
|
EBITDA | -9.50 -9.50 |
46%
46%
|
EBIT (Operating Income) EBIT | -9.76 -9.76 |
45%
45%
|
Net Profit | -13 -13 |
30%
30%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Addex Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of drugs for human health. It develops novel, orally available, and small molecule allosteric modulators for neurological disorders. The company was founded by Vincent Mutel, Timothy Dyer, and Mark Epping-Jordan in 2002 and is headquartered in Geneva, Switzerland.
Head office | Switzerland |
CEO | Tim Dyer |
Employees | 23 |
Founded | 2002 |
Website | www.addextherapeutics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.